Omeros (OMER) just absorbed a clear regulatory setback in Europe. The EMA’s CHMP upheld its negative view on narsoplimab for TA-TMA after re-examining the marketing application. At a share price of US...
Source LinkOmeros (OMER) just absorbed a clear regulatory setback in Europe. The EMA’s CHMP upheld its negative view on narsoplimab for TA-TMA after re-examining the marketing application. At a share price of US...
Source Link
Comments